Results 51 to 60 of about 504,627 (268)

Measurement of event-related potentials and placebo [PDF]

Serbian Journal of Electrical Engineering, 2014
ERP is common abbreviation for event-related brain potentials, which are measured and used in clinical practice as well as in research practice. Contemporary studies of placebo effect are often based on functional neuromagnetic resonance (fMRI),
Sovilj Platon, Ković Vanja, Biro Mikloš, Radak Marin, Mitrović Zoran   +4 more
doaj   +1 more source

Risk of Retinopathy Associated with Long‐Term Use of Hydroxychloroquine in Patients with Rheumatic Diseases: A Systematic Review and Meta‐Analysis

Arthritis Care &Research, EarlyView.
Objective We aimed to estimate the prevalence and cumulative incidence of hydroxychloroquine retinopathy (HCQ‐R) and its risk factors among patients receiving long‐term HCQ with rheumatic diseases through a systematic review and meta‐analysis of observational studies that used spectral‐domain optical coherence tomography (SD‐OCT) for screening ...
Narsis Daftarian, Chloe Yue, Steve D Levasseur, Hui Xie, J. Antonio Avina‐Zubieta   +4 more
wiley   +1 more source

Safety of Prescription Nonsteroidal Anti‐inflammatory Drugs in Adults With Inflammatory Bowel Disease: Data From a Large Administrative Claims Cohort

Arthritis Care &Research, EarlyView.
Objective The concern that nonsteroidal anti‐inflammatory drugs (NSAIDs) may precipitate flares of inflammatory bowel disease (IBD) has limited their use in managing musculoskeletal symptoms in those with IBD, but safety data are mixed. Methods This retrospective cohort study included patients with IBD aged at least 18 years from Optum's deidentified ...
Adam S. Mayer, Rui Xiao, Meenakshi Bewtra, Michael D. George, Pamela F. Weiss   +4 more
wiley   +1 more source

Elbasvir/Grazoprevir for HCV Infection in Russia: A Randomized Trial

Hepatic Medicine: Evidence and Research, 2020
Konstantin Zhdanov,1 Vasily Isakov,2 Eduard Burnevich,3 Svetlana Kizhlo,4 Igor Bakulin,5 Vadim Pokrovsky,6 Liwen Liang,7 Peggy Hwang,7 Rohit Talwani,7 Barbara A Haber,7 Michael N Robertson7 1Military Medical Academy n.a. S.M. Kirov, St.
Zhdanov K, Isakov V, Burnevich E, Kizhlo S, Bakulin I, Pokrovsky V, Liang L, Hwang P, Talwani R, Haber BA, Robertson MN   +10 more
doaj  

A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omiprazole in the treatment of cutaneous leishmaniasis [PDF]

Journal of Vector Borne Diseases, 2008
Background & objectives: Pentavalent antimony compounds are the first line of drugs in the treatment of cutaneous leishmaniasis. However, because of their potential toxic effects, many investigations are performed to find an effective and safe treatment ...
M.A. Nilforoushzadeh, F. Jaffary, N. Ansari, A.H. Siadat, Z. Nilforoushan, A. Firouz   +5 more
doaj  

Placebos in the clinic [PDF]

Journal of the Royal Society of Medicine, 2013
In 1954, it was reported in The Lancet that ‘Those who have qualms of conscience about prescribing pharmacologically useless medicines tend to use semi-placebos, such as vitamins, in the vague hope that these may do some good’.1 Except that the reasons for writing the prescriptions may not be quite so innocent, the same holds true today, decades into ...
openaire   +2 more sources

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS‐DAI)

Arthritis Care &Research, Accepted Article.
Objective VEXAS syndrome is characterized by a complex spectrum of inflammatory and hematologic manifestations. Clinical research to identify effective therapies is urgently needed but is hindered by the lack of validated outcome measures. A VEXAS‐specific disease activity index (DAI) is an essential tool for reliably capturing changes in disease ...
Kevin Byram, Heřman Mann, Danielle Hammond, Onima Chowdhury, Sinisa Savic, Yohei Kirino, Carmelo Gurnari, Maël Heiblig, Thibault Comont, Arsène Mekinian, Mrinal M. Patnaik, Lachelle D. Weeks, Gary Ho, Adam Al‐Hakim, Scott Goldberg, Marcela A. Ferrada, Sophie Georgin‐Lavialle, Peter C. Grayson, Emma M. Groarke, Bhavisha Patel, Megan Sullivan, Sarah A. Buckley, Bryan G. Harder, Raman Garcha, David B. Beck, Matthew J. Koster   +25 more
wiley   +1 more source

Developing evidence-based guidelines for describing potential benefits and harms within patient information leaflets/sheets (PILs) that inform and do not cause harm (PrinciPILs)

Health Technology Assessment
Background Variation in the way information about potential trial intervention benefits and harms is conveyed within patient information leaflets can cause avoidable information-induced (‘nocebo’) harm, research waste, and may be unethical. Objectives To
Jeremy Howick, Martina Svobodova, Shaun Treweek, Katie Gillies, Adrian Edwards, Peter Bower, Jennifer Bostock, Nina Jacob, Kerenza Hood   +8 more
doaj   +1 more source

Randomisation in a clinical trial: is it feasible in the Ebola crisis? If it is, then which method is suitable?

Southern African Journal of Infectious Diseases, 2016
Randomisation is an integral component of any sensible clinical trial. Randomisation is the only way we can be sure that the patients have been allocated into the treatment arms with as minimum bias as possible, and that the treatment arms are similar ...
Jesca M. Batidzirai
doaj   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

Advanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang, Kejia Li, Ning Wang, Zhen Li, Zhiyong Zhang, Rocky S. Tuan, Yangzi Jiang   +6 more
wiley   +1 more source